Icones novae. [A]

Aboae : [Johan Larsson Wall] 1683

'La Manteria'. Pinturas murales de la iglesia de Santo Tomás de Villanueva

La iglesia de Santo Tomás de Villanueva de Zaragoza es lo único que se conserva de lo que fuera el convento de agustinos observantes, llamado popularmente convento de la Mantería por ubicarse en la plaza del mismo nombre. Fué edificada entre 1663 y 1683 bajo el patronazgo del arzobispo de Zaragoza don Francisco Gamboa. Es un edificio barroco construido en ladrillo, con planta de cruz latina, de una sola nave, cubierta en sus tramos y brazos por cúpulas elípticas, siendo semiesférica la del crucero. Lo más destacable del edificio es su decoración mural. En un principio las pinturas cubrían la totalidad de las paredes y bóvedas. Los avatares históricos, desamortización y posterior empleo como almacén, así como el deterioro por efecto de la humedad, han hecho que sólo hayan llegado hasta nosotros las pinturas de las cúpulas. La ejecución de la pintura se debe al pintor de cámara de Carlos II, Claudio Coello, ayudado por su discípulo Sebastián Muñoz y por una serie de pintores locales. Claudio Coello trabajó entre 1683 y 1684, prolongándose las tareas hasta 1686.

Reseña de Andreu Bosch i Rodoreda, El lèxic alguerès de l'agricultura i la ramaderia entre els segles XVII i XVIII. Barcelona: IEC, 2012

Tot i que l"obra no ho explicita, puc testimoniar que aquesta recull, reelabo- rat i polit, el contingut de la tesi doctoral del seu autor, que, amb un títol més llarg i específic [La interferència dels parlars sards en el català de l"Alguer entre els segles xvii i xviii. Estudi del lèxic a través dels Registres de danys de la «Barracelleria» (1683-1829)], es va presentar a la Universitat de Barcelona el novembre de 2007 i vaig tenir l"oportunitat de llegir com a membre del tribunal corresponent.

Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate antibody-dependent cellular cytotoxicity upon Fc receptor stimulation is compromised, but the underlying mechanisms are largely unclear. We report here that NK-cells activation-dependently produce the tumor necrosis factor family member 'B-cell activating factor' (BAFF) in soluble form with no detectable surface expression, also in response to Fc receptor triggering by therapeutic CD20-antibodies. BAFF in turn enhanced the metabolic activity of primary CLL cells and impaired direct and Rituximab-induced lysis of CLL cells without affecting NK reactivity per se. The neutralizing BAFF antibody Belimumab, which is approved for treatment of systemic lupus erythematosus, prevented the effects of BAFF on the metabolism of CLL cells and restored their susceptibility to direct and Rituximab-induced NK-cell killing in allogeneic and autologous experimental systems. Our findings unravel the involvement of BAFF in the resistance of CLL cells to NK-cell antitumor immunity and Rituximab treatment and point to a benefit of combinatory approaches employing BAFF-neutralizing drugs in B-cell malignancies.

Cost-benefit analysis of an enhanced recovery protocol for pancreaticoduodenectomy.

BACKGROUND: Enhanced recovery after surgery (ERAS) programmes have been shown to decrease complications and hospital stay. The cost-effectiveness of such programmes has been demonstrated for colorectal surgery. This study aimed to assess the economic outcomes of a standard ERAS programme for pancreaticoduodenectomy. METHODS: ERAS for pancreaticoduodenectomy was implemented in October 2012. All consecutive patients who underwent pancreaticoduodenectomy until October 2014 were recorded. This group was compared in terms of costs with a cohort of consecutive patients who underwent pancreaticoduodenectomy between January 2010 and October 2012, before ERAS implementation. Preoperative, intraoperative and postoperative real costs were collected for each patient via the hospital administration. A bootstrap independent t test was used for comparison. ERAS-specific costs were integrated into the model. RESULTS: The groups were well matched in terms of demographic and surgical details. The overall complication rate was 68 per cent (50 of 74 patients) and 82 per cent (71 of 87 patients) in the ERAS and pre-ERAS groups respectively (P = 0·046). Median hospital stay was lower in the ERAS group (15 versus 19 days; P = 0·029). ERAS-specific costs were euro922 per patient. Mean total costs were euro56 083 per patient in the ERAS group and euro63 821 per patient in the pre-ERAS group (P = 0·273). The mean intensive care unit (ICU) and intermediate care costs were euro9139 and euro13 793 per patient for the ERAS and pre-ERAS groups respectively (P = 0·151). CONCLUSION: ERAS implementation for pancreaticoduodenectomy did not increase the costs in this cohort. Savings were noted in anaesthesia/operating room, medication and laboratory costs. Fewer patients in the ERAS group required an ICU stay.

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants.

One of the global targets for non-communicable diseases is to halt, by 2025, the rise in the age-standardised adult prevalence of diabetes at its 2010 levels. We aimed to estimate worldwide trends in diabetes, how likely it is for countries to achieve the global target, and how changes in prevalence, together with population growth and ageing, are affecting the number of adults with diabetes. We pooled data from population-based studies that had collected data on diabetes through measurement of its biomarkers. We used a Bayesian hierarchical model to estimate trends in diabetes prevalence-defined as fasting plasma glucose of 7.0 mmol/L or higher, or history of diagnosis with diabetes, or use of insulin or oral hypoglycaemic drugs-in 200 countries and territories in 21 regions, by sex and from 1980 to 2014. We also calculated the posterior probability of meeting the global diabetes target if post-2000 trends continue. We used data from 751 studies including 4,372,000 adults from 146 of the 200 countries we make estimates for. Global age-standardised diabetes prevalence increased from 4.3% (95% credible interval 2.4-7.0) in 1980 to 9.0% (7.2-11.1) in 2014 in men, and from 5.0% (2.9-7.9) to 7.9% (6.4-9.7) in women. The number of adults with diabetes in the world increased from 108 million in 1980 to 422 million in 2014 (28.5% due to the rise in prevalence, 39.7% due to population growth and ageing, and 31.8% due to interaction of these two factors). Age-standardised adult diabetes prevalence in 2014 was lowest in northwestern Europe, and highest in Polynesia and Micronesia, at nearly 25%, followed by Melanesia and the Middle East and north Africa. Between 1980 and 2014 there was little change in age-standardised diabetes prevalence in adult women in continental western Europe, although crude prevalence rose because of ageing of the population. By contrast, age-standardised adult prevalence rose by 15 percentage points in men and women in Polynesia and Micronesia. In 2014, American Samoa had the highest national prevalence of diabetes (>30% in both sexes), with age-standardised adult prevalence also higher than 25% in some other islands in Polynesia and Micronesia. If post-2000 trends continue, the probability of meeting the global target of halting the rise in the prevalence of diabetes by 2025 at the 2010 level worldwide is lower than 1% for men and is 1% for women. Only nine countries for men and 29 countries for women, mostly in western Europe, have a 50% or higher probability of meeting the global target. Since 1980, age-standardised diabetes prevalence in adults has increased, or at best remained unchanged, in every country. Together with population growth and ageing, this rise has led to a near quadrupling of the number of adults with diabetes worldwide. The burden of diabetes, both in terms of prevalence and number of adults affected, has increased faster in low-income and middle-income countries than in high-income countries. Wellcome Trust.

De miraculis

Invocatio: I.S.A: - Ded.: Jonas Bruzelius.

De fabulis philosophorum

Invocatio: Q.F.F.Q.S.

L'Univers

1872/01/26 (Numéro 1683).

L'Univers

1871/10/25 (Numéro 1593).

Yksilöllisten kulttuurimatkailijoiden, anti-turistien ja travellereiden oppi-isä

Kirjallisuusarvostelu

Drenagem endoscópica de abscesso pancreático

Surgical drainage is still considered the gold standard treatment of pancreatic abscess. Patients with high surgical risk, however, require alternative therapy. The authors report three cases of pancreatic abscess that were treated endoscopically. In patients who met endoscopic drainage criteria, treatment was effective, though one case did require surgical intervention as a result of gastric puncture point bleeding. After this initial experience, we believe that endoscopic drainage should be considered in selected cases.